Search - tctmd.com

Displaying 141 - 160 of 262

Sort: Relevancy | Date

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

US Dobutamine Shortage a ‘Huge Problem’—What’s the Solution?

Shelley Wood

July 15, 2022

News Opinion CV Team Dispatch

July 2022 News Roundup

L.A. McKeown

July 01, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Daily News

COVID-19 Vaccination Tied to Better Outcomes in HF Patients

Todd Neale

June 09, 2022

News Opinion CV Team Dispatch

June 2022 News Roundup

L.A. McKeown

June 01, 2022

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Opinion CV Team Dispatch

May 2022 News Roundup

L.A. McKeown

May 01, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Opinion CV Team Dispatch

April 2022 News Roundup

L.A. McKeown

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

Advertisement

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

US Dobutamine Shortage a ‘Huge Problem’—What’s the Solution?

July 2022 News Roundup

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

COVID-19 Vaccination Tied to Better Outcomes in HF Patients

June 2022 News Roundup

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

May 2022 News Roundup

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 2022 News Roundup

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content